[Updated at 20:00 on 20 July]
When the story about the CAPRISA 004 trial results broke on 19 July, there was flurry of public statements and news stories that reflected the promising nature of the results and the impact they could eventually have on HIV prevention scale up. The trial tested the safety and effectiveness of 1% tenofovir gel, an antiretroviral-based vaginal microbicide among nearly 900 women at two sites in South Africa. Trial results were presented at AIDS 2010 on 20 July.
We have gathered some links and statements for more information.